TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. IMMUNOMODULATORS MARKET, BY PRODUCT
6.1. Overview
6.2. Immunosuppressants
6.3. Immunostimulants
6.4. Others
7. IMMUNOMODULATORS MARKET, BY APPLICATION
7.1. Overview
7.2. Respiratory
7.3. Human Immunodeficiency Virus (HIV)
7.4. Oncology
7.5. Others
8. IMMUNOMODULATORS MARKET, BY END USER
8.1. Overview
8.2. Hospitals
8.3. Homecare
8.4. Specialty Clinics
8.5. Others
9. IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL
9.1. Overview
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.5. Others
10. IMMUNOMODULATORS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Immunomodulators Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Immunomodulators Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure. 2022
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd (Switzerland)
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Johnson & Johnson Services, Inc.(U.S.)
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Takeda Pharmaceutical Company Limited (Japan)
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Amgen Inc.(U.S.)
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Novartis AG (Switzerland)
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. GlaxoSmithKline plc.(U.K.)
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Merck & Co., Inc.(U.S.)
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. SQUAREX.(U.S.)
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. BioRap Technologies LTD (Israel)
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Pfizer Inc.(U.S.)
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 IMMUNOMODULATORS MARKET, SYNOPSIS, 2018-2032
TABLE 2 IMMUNOMODULATORS MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 4 IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 5 IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 6 IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 11 US: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 12 US: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 13 US: IMMUNOMODULATORS MARKET, BYEND USER, 2018-2032 (USD BILLION)
TABLE 14 US: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 15 CANADA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 16 CANADA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 17 CANADA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 18 CANADA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 3 EUROPE: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 4 EUROPE: IMMUNOMODULATORS MARKET, BYDISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 5 GERMANY: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 6 GERMANY: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 7 GERMANY: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 8 GERMANY: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 FRANCE: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 10 FRANCE: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 11 FRANCE: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 12 FRANCE: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 13 ITALY: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 14 ITALY: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 15 ITALY: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 16 ITALY: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 17 SPAIN: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 18 SPAIN: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 19 SPAIN: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 20 SPAIN: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 21 UK: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 22 UK: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 23 UK: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 24 UK: IMMUNOMODULATORS MARKET, BYDISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 33 JAPAN: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 34 JAPAN: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 35 JAPAN: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 36 JAPAN: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 37 CHINA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 38 CHINA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 39 CHINA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 40 CHINA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 41 INDIA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 42 INDIA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 43 INDIA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 44 INDIA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 45 AUSTRALIA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 46 AUSTRALIA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 47 AUSTRALIA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 48 AUSTRALIA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 65 AFRICA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 66 AFRICA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 67 AFRICA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 68 AFRICA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: IMMUNOMODULATORS MARKET, BY PRODUCT, 2018-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: IMMUNOMODULATORS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: IMMUNOMODULATORS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: IMMUNOMODULATORS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE IMMUNOMODULATORS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE IMMUNOMODULATORS MARKET
FIGURE 4 IMMUNOMODULATORS MARKET, SHARE (%), BY PRODUCT, 2022
FIGURE 5 IMMUNOMODULATORS MARKET, SHARE (%), BY APPLICATION, 2022
FIGURE 6 IMMUNOMODULATORS MARKET, SHARE (%), BY END USER, 2022
FIGURE 7 IMMUNOMODULATORS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 8 IMMUNOMODULATORS MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 NORTH AMERICA: IMMUNOMODULATORS MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 EUROPE: IMMUNOMODULATORS MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 ASIA-PACIFIC: IMMUNOMODULATORS MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 REST OF THE WORLD: IMMUNOMODULATORS MARKET, SHARE (%), BY REGION, 2022
FIGURE 13 IMMUNOMODULATORS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 14 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): SWOT ANALYSIS
FIGURE 16 JOHNSON & JOHNSON SERVICES, INC.(U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 JOHNSON & JOHNSON SERVICES, INC.(U.S.): SWOT ANALYSIS
FIGURE 18 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN): SWOT ANALYSIS
FIGURE 20 AMGEN INC.(U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 AMGEN INC.(U.S.): SWOT ANALYSIS
FIGURE 22 NOVARTIS AG (SWITZERLAND).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 NOVARTIS AG (SWITZERLAND).: SWOT ANALYSIS
FIGURE 24 GLAXOSMITHKLINE PLC.(U.K.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 GLAXOSMITHKLINE PLC.(U.K.): SWOT ANALYSIS
FIGURE 26 MERCK & CO., INC.(U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 MERCK & CO., INC.(U.S.): SWOT ANALYSIS
FIGURE 28 SQUAREX.(U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SQUAREX.(U.S.): SWOT ANALYSIS
FIGURE 30 BIORAP TECHNOLOGIES LTD (ISRAEL): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 BIORAP TECHNOLOGIES LTD (ISRAEL): SWOT ANALYSIS
FIGURE 32 PFIZER INC.(U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 PFIZER INC.(U.S.): SWOT ANALYSIS
